* More than 25 years of experience* Consultant Physician, BMI The Clementine Churchill Hospital (present) * Consultant Physician, St Mary's Hospital - Lindo Wing (present)* Consultant Physician, The London Clinic (present)* Consultant Physician, St Mary€™s and Hammersmith Hospitals* Consultant Physician, Imperial College London Healthcare NHS Trust ...

* Specialist Registrar training in Gastroenterology, St Mary€™s Hospital and University College Hospital (2002 - 2007)* â‚¬â€¹PhD, Imperial College London (2003) * Membership of the Royal College of Physicians (1998)* MBBS, Guy€™s Hospital Medical School, University of London (1994)* BSc Honours Immunology (2:1), Guy's and St Thomas' Medical School, University of London (1992)* Over 100 Publications in the peer reviewed medical literature* Supervises PhD students and BSc students ...

* â‚¬â€¹Association of Physicians of Great Britain and Ireland (2014) * American Association for the Study of the Liver Diseases (2008 - present) * â‚¬â€¹International Liver Cancer Association (ILCA) (2008 - present)  * British Society of Gastroenterology (2007 - present)* European Association for the Study of the Liver (EASL) (2007 - present)* British Association for the Study of the Liver (2007 - present) * British Medical Association (2004 - present)* Medical Protection Society (MPS)* Member of the British Liver Trust Clinical Advisory Community * Membership of the Royal College of Physicians (1998)* Fellow of the Royal College of Physicians (2011)  €‹* Senior Fellow of the Higher Education Academy (2010) ...

* British Liver Trust Award for Liver Cancer Research* Twice winner of: European Association for Study of Liver Disease (EASL) Annual Young Investigator Travel Bursary for Presentation; EASL Conferences in Rotterdam (May 2000) and Madrid (April 2002) * Annual Young Scientist Travel Award for Presentation, American Association for Study of Liver Disease (AASLD) presentation Dallas, USA (2000)* Royal College of Radiologists National Annual Undergraduate Prize in Clinical Oncology (1993)* Royal College of Pathologists National Elective Prize (1993)* Cancer Research Campaign National Annual Elective Prize (1993)* Nuffield Research Scholarship for research in cervical cancer vaccines (1992)* Bernard Sunley Award to fund intercalated BSc (1991)* Scholarship to Westminster School (1986) ...

* Banales J, Marin J, Lamarca A, Rodrigues P, Khan SA, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Rev Gastroenterol Hepatol. 2020 Jun 30. doi: 10.1038/s41575-020-0310-z.* Pericleous M and Khan SA. Epidemiology of HPB Malignancy in the Elderly. EJSO 2020; (in press) * Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD and Khan SA. Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020. 72(1):95-103. doi: 10.1016/j.jhep.2019.09.007.* Dumenci OE, Abellona MR U, Khan SA, Holmes E, Taylor-Robinson SD. Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction. J Hepat Carcinoma 2020; 7: 1-9.* Yousaf A, Kim J, Eliahoo J, Taylor-Robinson SD and Khan SA. Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-analysis. J Clin Exp Hepatology 2019; J Clin Exp Hepatol. 2019 Nov-Dec;9(6):740-748. doi: 10.1016/j.jceh.2019.08.001. Epub 2019 Aug 19.PMID: 31889756* Khan SA, Genus T, Morement H, Murphy A, Rous B, Tataru B. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma €“ Letter to the Editor. J Hepatology 2019; 71:1261-1262* Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and Risk Factors. Liver Int 2019. DOI 10.1111/liv.14095* Wadsworth CA, Dixon PH, Taylor-Robinson SD, Kim JU, Zabron AA, Wong JH, Chapman MH, McKay SC, Spalding DR, Wasan HS, Pereira SP, Thomas HC, Whittaker JC, Williamson C and Khan SA. Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a risk factor for Cholangiocarcinoma. J Clin Exp Hep 2019;9(2):171-175. doi: 10.1016/j.jceh.2018.06.521.* Mukherjee SK, Toledano MB, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PloS One 2019;14(4):e0212779. doi: 10.1371* Howell J, Atkinson SR, 1, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer 2019; 116: 56-66.* Appleby RN, Moghul I, Khan SA, Yee M, Manousou P, Dew T, Walters JRF. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: a prospective observational study. PloS One 2019; 25;14(1):e0211348. doi: 10.1371/journal.pone.0211348* Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nature Rev Clin Oncol 2018 15(2):95-111. doi: 10.1038/nrclinonc.2017.157..* Shabeer LL and Khan SA. Medical Students' Perception of Undergraduate Hepatology Teaching In The UK - A National Survey. Annual General Meeting of the British-Society-of-Gastroenterology. Gut 2018. BMJ Publishing Group. 67: A278-A278 (Conference Abstract).* Khan SA, McClements S, Reccia I, Evans J, Pai M and Sharma R. The Next Generation of Hepatocellular Cancer Experts €“ What do they think? Hepatic Onc 2017: 3(4), 213€“215.* Carruthers J, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP: Nationwide trends in non-alcoholic steatohepatitis in patients with and without diabetes between 2004 and 2014 in England. Diab Res Clin Prac 2017; 132:102-107.* Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan SA, Fowell A, McPherson S, Newsome PN, Oben J, Jeremy Tomlinson J, Tsochatzis E. Frontline Gastroenterology 2017;8:252€“259.* Liu NJ, Chapman R, Lin Y, Bentham A, Tyreman M, Philips N, Khan SA, Molly M. Stevens. Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. Nanoscale 2016; 8(23):11834-9.* Howell J, Khan SA, Knapp S, Thursz MR, Sharma R. The clinical role of circulating free tumour DNA in gastrointestinal malignancy. Transl Res. 2016; pii: S1931-5244(16)30461-3.* Howell J, Khan SA. The Role of miRNAs in Cholangiocarcinoma. Hepat Oncol 2016: 3(2):167-180.* Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T. ESMO Clinical Practice Guidelines On behalf of the ESMO Guidelines Working Group: Buliary Tract Cancer. Ann Oncol. 2016;27(s5):v28-v37.* International Webinar on the Management of Hepatocellular Carcinoma for Bayer in the COVID Era (2020)* British Society of Gastroenterology Committee for update of the UK guidelines on the Management of Cholangiocarcinoma (2020)* Plenary Lecture at BASL: What€™s New in Cholangiocarcinoma (2019) ...

* Advisor to Liver Patient Groups and Charities including AMMF, PSC Support and the British Liver Trust

* Professor of Practice (Hepatology), Imperial College London* Course Director of the Gastroenterology and Hepatology BSc programme, Imperial College London * Director of Clinical Studies, St Mary€™s Hospital Campus (2013 €“ 2016)* Deputy Admissions Tutor, Imperial Medical School (2012 - present) ...